[1] Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, Matà S, Kremens D, Vitaliani R, Geschwind MD, Bataller L, Kalb RG, Davis R, Graus F, Lynch DR, Balice-Gordon R, Dalmau J. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location[J]. Ann Neurol, 2009, 65:424-434.
[2] Byun JI, Lee ST, Jung KH, Sunwoo JS, Moon J, Kim TJ, Lim JA, Kim S, Kim DY, Han SH, Jang H, Suh HI, Cho AH, Kim DW, Shin JW, Koo YS, Choi WC, Lee WW, Choi N, Kim S, Nam H, Koo DL, Kim M, Lim BC, Chae JH, Kim KJ, Jeon D, Park KI, Jung KY, Kim M, Chu K, Lee SK. Prevalence of antineuronal antibodies in patients with encephalopathy of unknown etiology:data from a nationwide registry in Korea[J]. J Neuroimmunol, 2016, 293:34-38.
[3] Höftberger R, van Sonderen A, Leypoldt F, Houghton D, Geschwind M, Gelfand J, Paredes M, Sabater L, Saiz A, Titulaer MJ, Graus F, Dalmau J. Encephalitis and AMPA receptor antibodies:novel findings in a case series of 22 patients[J]. Neurology, 2015, 84:2403-2412.
[4] Rosenthal-Simons A, Durrant AR, Heresco-Levy U. Autoimmune-induced glutamatergic receptor dysfunctions:conceptual and psychiatric practice implications[J]. Eur Neuropsychopharmacol, 2013, 23:1659-1671.
[5] Yuan JH, Huang W, Duan CX. A case of AMPA2 antibody positive autoimmune encephalitis with arrhythmia[J]. Zhongguo Xian Dai Yi Xue Za Zhi, 2018, 28:126-128.[袁建华, 黄卫, 段春霞. 合并心律失常的AMPA2型抗体阳性自身免疫性脑炎1例[J]. 中国现代医学杂志, 2018, 28:126-128.]
[6] McCabe BF. Autoimmune sensorineural hearing loss[J]. Ann Otol Rhinol Laryngol, 1979, 88:585-589.
[7] Tomiyama M, Rodriguez-Puertas R, Cortés R, Christnacher A, Sommer B, Pazos A, Mengod G. Differential regional distribution of AMPA receptor subunit messenger RNAs in the human spinal cord as visualized by in situ hybridization[J]. Neuroscience, 1996, 75:901-915.
[8] Wei YC, Liu CH, Lin JJ, Lin KJ, Huang KL, Lee TH, Chang YJ, Peng TI, Lin KL, Chang TY, Chang CH, Kuo HC, Chang KH, Cheng MY, Huang CC. Rapid progression and brain atrophy in anti-AMPA receptor encephalitis[J]. J Neuroimmunol, 2013, 261:129-133.
[9] Laurido-Soto O, Brier MR, Simon LE, McCullough A, Bucelli RC, Day GS. Patient characteristics and outcome associations in AMPA receptor encephalitis[J]. J Neurol, 2019, 266:450-460.
[10] Joubert B, Kerschen P, Zekeridou A, Desestret V, Rogemond V, Chaffois MO, Ducray F, Larrue V, Daubail B, Idbaih A, Psimaras D, Antoine JC, Delattre JY, Honnorat J. Clinical spectrum of encephalitis associated with antibodies against the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor:case series and review of the literature[J]. JAMA Neurol, 2015, 72:1163-1169.
[11] Dogan Onugoren M, Deuretzbacher D, Haensch CA, Hagedorn HJ, Halve S, Isenmann S, Kramme C, Lohner H, Melzer N, Monotti R, Presslauer S, Schäbitz WR, Steffanoni S, Stoeck K, Strittmatter M, Stögbauer F, Trinka E, von Oertzen TJ, Wiendl H, Woermann FG, Bien CG. Limbic encephalitis due to GABAB and AMPA receptor antibodies:a case series[J]. J Neurol Neurosurg Psychiatry, 2015, 86:965-972.
[12] Branch of Neurology, Chinese Medical Association. Expert consensus on diagnosis and treatment of autoimmune encephalitis in China[J]. Zhonghua Shen Jing Ke Za Zhi, 2017, 50:91-98.[中华医学会神经病学分会. 中国自身免疫性脑炎诊治专家共识[J]. 中华神经科杂志, 2017, 50:91-98.]
[13] Urriola N, Soosapilla K, Drummond J, Thieben M. Fulminant thymomatous AMPAR-antibody limbic encephalitis with hypertonic coma, bruxism, an isoelectric electroencephalogram and temporal cortical atrophy, with recovery[J]. BMJ Case Rep, 2019, 12:E227893.
[14] Ishiura H, Matsuda S, Higashihara M, Hasegawa M, Hida A, Hanajima R, Yamamoto T, Shimizu J, Dalmau J, Tsuji S. Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab[J]. Neurology, 2008, 71:1921-1923.
[15] Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. Immune therapy in autoimmane encephalitis:a systematic review[J]. Expert Rev Neurother, 2015, 15:1391-1419.
[16] Seki M, Suzuki S, Iizuka T, Shimizu T, Nihei Y, Suzuki N, Dalmau J. Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis[J]. J Neurol Neurosurg Psychiatry, 2008, 79:324-326.
[17] Bao SZ, Han JZ, Cao DH, Kang ZL, Zhu JG. Diagnosis and treatment of anti-AMPA2 receptor antibody encephalitis with breast cancer[J]. Zhong Feng Yu Shen Jin Ji Bing Za Zhi, 2017, 34:747-748.[鲍双振, 韩敬哲, 曹端华, 康志雷, 朱建国. 抗AMPA2受体抗体脑炎合并乳腺癌诊治体会[J]. 中风与神经疾病杂志, 2017, 34:747-748.]
[18] Samad N, Wong J. Anti-AMPA receptor encephalitis associated with medullary thyroid cancer[J]. BMJ Case Rep, 2018, 27:225745.
[19] Koh D, Lau T, Teoh E, Lau KK. An uncommon presentation of a primary bone tumor:anti-AMPA (anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor limbic/paraneoplastic encephalitis as a presenting feature of ewing sarcoma[J]. J Pediatr Hematol Oncol, 2018, 40:555-557.
[20] Omi T, Kinoshita M, Nishikawa A, Tomioka K, T, Ohmori Fukada K, Matsunaga H. Clinical relapse of anti-AMPAR encephalitis associated with recurrence of thymoma[J]. Intern Med, 2018, 57:1011-1013.
[21] Wu H, Zhao CB, Zhou L. A case report of anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor encephalitis[J]. Zhonghua Shen Jin Ke Za Zhi, 2015, 48:794-795.[吴慧, 赵重波, 周磊. 抗α-氨基-3-羟基-5-甲基-4-异唑丙酸受体抗体脑炎一例[J]. 中华神经科杂志, 2015, 48:794-795.]
[22] Zhu H, Hou YB, Gao JG, Zhao T, Zhou CK, Liu JY. Limbic encephalitis associated with antibodies against the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor:a case report[J]. Neuro Endocrinol Lett, 2018, 39:85-87.